Response to comment on ‘Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial’

被引：0
|
作者：
M L Subramanian
机构：
[1] Boston University School of Medicine and the VA Boston Healthcare System,Department of Ophthalmology
来源：
Eye | 2011年 / 25卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：820 / 820
相关论文
共 50 条
  • [41] A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration
    Russo, Andrea
    Costagliola, Ciro
    Delcassi, Luisa
    Romano, Mario R.
    Semeraro, Francesco
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2013, 97 (10) : 1273 - 1276
  • [42] A 1-YEAR RETROSPECTIVE REVIEW OF RANIBIZUMAB FOR NAIVE NONSUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
    Arias, Luis
    Ruiz-Moreno, Jose M.
    Gomez-Ulla, Francisco
    Fernandez, Maribel
    Montero, Javier
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (10): : 1444 - 1449
  • [43] Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment
    Bloch, Sara B.
    la Cour, Morten
    Sander, Birgit
    Hansen, Louise K. H.
    Fuchs, Josefine
    Lund-Andersen, Henrik
    Larsen, Michael
    ACTA OPHTHALMOLOGICA, 2013, 91 (01) : 42 - 47
  • [44] Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration
    Feng, Xue-Feng
    Constable, Ian J.
    McAllister, Ian L.
    Isaacs, Timothy
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2011, 4 (01) : 85 - 88
  • [45] Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes
    Meidong Zhu
    Jamie K. Chew
    Geoffrey K. Broadhead
    Kehui Luo
    Nichole Joachim
    Thomas Hong
    Adil Syed
    Andrew A. Chang
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253 : 1217 - 1225
  • [46] Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes
    Zhu, Meidong
    Chew, Jamie K.
    Broadhead, Geoffrey K.
    Luo, Kehui
    Joachim, Nichole
    Hong, Thomas
    Syed, Adil
    Chang, Andrew A.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2015, 253 (08) : 1217 - 1225
  • [47] Correlation Between Visual Acuity and Duration of Symptoms in the ABC Trial - A Double-Masked, Randomised Controlled Trial of Intravitreal Avastin (Bevacizumab) Injections for the Treatment of Choroidal Neovascularization (CNV) in Age-Related Macular Degeneration (AMD)
    Esposti, S. Degli
    Patel, P. J.
    Tufail, A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [48] Infographic: ranibizumab or bevacizumab treat & extend for neovascular age-related macular degeneration (AMD): LUCAS trial
    Barai, Ishani
    Sivaprasad, Sobha
    Henein, Christin
    EYE, 2025, 39 (SUPPL1) : 129 - 131
  • [49] Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration
    Ian J Constable
    Ian L McAllister
    Timothy Isaacs
    International Journal of Ophthalmology, 2011, (01) : 85 - 88
  • [50] A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design
    Praveen J Patel
    Catey Bunce
    Adnan Tufail
    Trials, 9
12345